The example of CaPSURE: lessons learned from a national disease registry by Porten, Sima P. et al.
TOPIC PAPER
The example of CaPSURE: lessons learned from a national disease
registry
Sima P. Porten • Matthew R. Cooperberg •
Badrinath R. Konety • Peter R. Carroll
Received: 21 December 2010/Accepted: 2 February 2011/Published online: 24 February 2011
 The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract
Introduction Although randomized controlled trials (RCTs)
remain the gold standard for determining evidence-based
clinical practices, large disease registries that enroll large
numbers of patients have become paramount as a relatively
cost-effective additional tool.
Methods We highlight the advantages of disease regis-
tries focusing on the example of prostate cancer and the
Cancer of the Prostate Strategic Urologic Research
Endeavor (CaPSURE
TM) registry.
Results CaPSURE collects approximately 1,000 clinical
and patient-reported variables, in over 13,000 men that are
enrolled. Thus far, CaPSURE has yielded over 130 peer-
reviewed publications, with several others in press, in key
areas of risk migration, practice patterns, outcome predic-
tion, and quality of life outcomes.
Conclusions Disease registries, like CaPSURE comple-
ment RCTs and CaPSURE, have provided a means to
better understand many aspects of prostate cancer epide-
miology, practice patterns, oncologic and HRQOL out-
comes, and costs of care across populations. Specialized
observational disease registries such as CaPSURE provide
insight and have broad implications for disease manage-
ment and policy.
Keywords Prostatic neoplasms  CaPSURE  Disease
registries
Introduction
The randomized controlled trial (RCT) remains the gold
standard for informing evidence-based clinical practice,
in urology as in other medical domains. Limitations
include time, signiﬁcant expense, stringent inclusion
criteria, and resistance to randomization by clinicians and
patients. Ultimately, if patients enrolled in a RCT differ
from the larger population of patients with a given
condition, the external validity of the ﬁndings may be
questionable. Although these limitations can be mitigated
by utilizing specialized RCT designs (Table 1), disease
registries have emerged as an important complement to
RCTs. Disease registries, which accrue prospectively
identiﬁed cohorts and follow them regardless of soci-
odemographic characteristics, clinical variables, treatment
details or intermediate outcomes, have emerged as an
important complement to RCTs. This reﬂection of ‘‘real
world’’ treatment is a tremendous asset especially in
prostate cancer research as it provides a relatively cost-
effective tool to shed light on a disease with a long
natural history and rapidly changing management prac-
tices that are subject to many different clinical, scientiﬁc,
demographic, and economic dynamics. This article will
highlight some advantages of disease registries focusing
on the example of prostate cancer and the Cancer of
the Prostate Strategic Urologic Research Endeavor
(CaPSURE
TM) registry.
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trends in prostate cancer epidemiology, disease manage-
ment, oncologic outcomes, and health-related quality of
life (HRQOL) outcomes. It is a longitudinal, observational
database accruing data from a total of 40 urologic practice
sites over the history of the registry. The majority of sites
are community based, although four university-afﬁliated
centers, and Veterans Affairs (VA) medical centers are
included. Men with biopsy-proven cancer are invited to
join CaPSURE regardless of disease stage or treatment
history. Informed consent for participation is obtained
under institutional review board supervision.
CaPSURE collects approximately 1,000 clinical and
patient-reported variables. Clinical information is collected
by the treating urologist at baseline and with each follow-
up visit and includes history of prostate cancer diagnosis,
biopsies, pathology, staging tests, primary and subsequent
treatments (radical prostatectomy [RP], external beam
radiotherapy [EBRT], brachytherapy, primary and neoad-
juvant androgen deprivation therapy [PADT and NADT],
cryosurgery, and watchful waiting/active surveillance
[AS]), Karnofsky performance status scores, clinic proce-
dures, and medications. At enrollment and every 6 months
thereafter, a questionnaire is completed documenting
sociodemographic parameters, comorbidities, and HRQOL
using validated instruments. Other sections of the patient
questionnaires assess use of health services, with hospi-
talization data veriﬁed by discharge summary review.
Patients are treated according to their physicians’ usual
practices and patient preferences and are followed until time
of death or withdrawal from the study. Periodic, random
sample chart review ensures completeness and accuracy of
data collected and entered. Additional details regarding
project methodology have been reported previously [1].
CaPSURE is managed by the Department of Urology at the
UCSFHelenDillerFamilyComprehensiveCancerCenter.It
was funded from inception to 2007 through an unrestricted
education grant from TAP Pharmaceutical Products, Inc.,
and currently is supported through Abbott Labs (Chicago,
IL) and several collaborative Federal grants.
There are currently 13,821 men enrolled in CaPSURE.
The median patient age at diagnosis is 67, and 75% of men
are between 60 and 79 years of age. Most patients are
white, with approximately 10% black representation, and
3.5% Latino, Asian, and other ethnicities. There is a fairly
even distribution across socioeconomic strata, based on
education and income level. CaPSURE has yielded over
130 peer-reviewed publications, with several others in
press. A summary of some key research ﬁndings follows.
Trends in prostate cancer presentation and risk
Temporal trends in the PSA era in patient risk at diagnosis
are consistent with downward stage migration. In CaP-
SURE, the proportion of patients presenting with low-risk
disease (PSA\10 ng/mL, Gleason score\7 with no
pattern 4 or 5 disease on biopsy, and clinical stage T1 or T2
disease) has increased from 31% between 1989 and 1990 to
47% of patients between 2001 and 2002 and has remained
Table 1 Specialized classiﬁcations of randomized controlled trials
Type Description Strengths Limitations
Cluster Randomization of subjects as a group
rather than on individual basis
Can study interventions that cannot be directed
toward selected individuals
Can control for contamination across
individuals (i.e., when one individual’s
behavior can inﬂuence another’s)
Needs more subjects to reach statistical
power than standard RCT
Explanatory Individual randomization of very
selective subjects in a highly
controlled setting
Useful to test efﬁcacy (i.e., whether an
intervention causes a speciﬁc biologic
response)
Patients blinded
Excellent internal validity
Good for acute disease processes
External validity and applicability to
clinical practice is limited due to subject
selection
Pragmatic Individual randomization of non-
selective group of patients in a
regular clinical setting
Useful to test effectiveness of an intervention
in everyday practice
Good for chronic disease processes and
complex interventions
Excellent external validity and directly
applicable to clinical practice
Patients unblinded
Internal validity limited due to broad
inclusion criteria
Expertise-
based
Individual randomization of subjects
to an expertise in the intervention
in question
Useful when intervention is non-pharmacologic
(i.e., surgical procedures)
External validity limited to only those
patients receiving care from a physician
with expertise skills
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123relatively stable [2]. However, within this low-risk group,
there is a trend toward lower-risk characteristics (based on
PSA, clinical stage, and percent positive biopsy). Con-
versely, during the same time, men with high-risk disease
(PSA[20 ng/mL, Gleason 8-10 on biopsy, or stage T3)
have decreased from 41 to 29%. Although the rate of high-
risk prostate cancer has fallen, it has remained stable since
2000 and represents approximately 24% of patients in
recent studies [3]. There is no evidence in the CaPSURE
cohort of meaningful downward risk migration among
high-risk patients over the past 15 years.
Despite presentation with lower-risk disease due to
increased PSA screening, recent studies have observed a
disparity in prostate cancer presentation across sociode-
mographic groups. Dall’era et al. [4] examined 5,939 men
enrolled in CaPSURE from 1995 to 2007, and found that
patients who were older, less educated, and had Medicare
for insurance (as opposed to VA or private coverage) were
more likely to have intermediate or high-risk disease. Non-
white race was also associated with high-risk disease at
presentation (OR 1.83, 1.47–2.29, P\0.01). Clinically
insigniﬁcant disease (PSA\10 ng/mL,\33% of biopsy
cores involved, no Gleason pattern 4/5, and stage T1a or
T2a) was more common in younger men (\60 years old),
higher income/education, and men with private insurance.
Within this group, younger age and private insurance were
again associated with immediate treatment in lieu of AS.
Health services research and trends in disease
management
The majority of patients followed in CaPSURE were
diagnosed during the PSA era and treated in community-
based settings. One strength of this registry is that partic-
ipating physicians treat according to their usual practices
and patient preferences. CaPSURE provides a mix of
locales and practice types, reﬂecting current contemporary
urological practice at a national level. The CaPSURE sites
are not a random sample of the US population. However,
CaPSURE includes far richer clinical detail than popula-
tion-based sources such as the Surveillance Epidemiology
and End Results (SEER) database and SEER-Medicare and
therefore is an excellent data source for national studies of
disease management.
Imaging studies performed in men with prostate can-
cer may serve to facilitate optimal treatment planning.
However, staging studies are associated with low but def-
inite risks, signiﬁcant costs to the health care system, and
have minimal beneﬁt in patients with low-risk disease
characteristics. One early study from CaPSURE examined
the use of imaging tests for staging clinically localized
prostate cancer between 1989 and 1997. Kindrick et al. [5]
found widespread and consistent overuse in the rates of
bone scan, computed tomography, and magnetic resonance
imaging among patients with low likelihood of extrapros-
tatic disease. Follow-up analysis through 2001 showed that
rates of bone scan and computerized tomography use have
decreased in recent years with the greatest decreases in
patients with lower-risk cancer [6]. Whereas among early
CaPSURE patients, disease risk exerted no inﬂuence on the
likelihood of imaging, the more recent CaPSURE data have
illustrated a trend toward appropriate and evidence-based
use of imaging tests. This highlights the value of registries
such as CaPSURE that allows evaluation of adherence to
guidelines based on high-level evidence into common
clinical practice, as well as the extent to which evidence-
based medicine is practiced in urology.
Multiple recent CaPSURE studies have examined pat-
terns in treatment selection for patients diagnosed with
prostate cancer. An early study examined the use of ADT
in patients with localized disease and found a higher than
expected use of ADT monotherapy [7]. Among low-,
intermediate-, and high-risk patients, ADT monotherapy
rose dramatically, from 5 to 14%, 9 to 20%, and 33 to 48%,
respectively, from 1989–1990 to 2000–2001. PADT
monotherapy is considered to be investigational based on
the American Urological Association’s clinical practice
guidelines [8], and no controlled trials have established
efﬁcacy of this approach.
With decreasing risk migration, it would be expected
that the use of AS would increase since more men are
presenting with favorable risk disease. An early study of
temporal trends found that the use of AS reached a nadir of
5.5% in 2000–2001 from 9.5% in 1992–1994, with the
largest declines in low-risk patients (6.2%), although recent
improvement to 10.2% in 2004–2006 was observed [2].
Another study by Barocas et al. [9] found that between
1999 and 2004, 16.4% of men met strict surveillance cri-
teria (PSA\10 ng/mL, clinical T1 or T2a, prostate-spe-
ciﬁc antigen density PSAD\0.15, \33% biopsy cores
positive, and absence of Gleason pattern 4/5 on biopsy),
but only 9% of men in this low-risk category chose sur-
veillance, highlighting the underuse of this management
strategy in the United States.
In addition to the initial decline in AS, a decrease was
observed in EBRT from 13% in 1993–1995 to 7% in
1999–2001 and RP (55–52%) and increases in PADT
(7–12%) and brachytherapy (4–22%) in low-risk patients
[10]. This treatment trend remained present in men
[75 years with the use of surveillance in only 24%,
declining from 52%, PADT use increasing from 23 to 30%,
and brachytherapy from 3 to 31%. A reversal of this trend
was observed with a decrease in brachytherapy to 13% in
2005–2006, a decrease in PADT to 6.6%, and an increase
in RP to 60% [2].
World J Urol (2011) 29:265–271 267
123Overall, it appears that prostate cancer risk drives
treatment selection in conjunction with age, comorbidity,
and socioeconomic status. However, a recent analysis in
CaPSURE examining practice patterns in the primary
treatment of localized prostate cancer conﬁrmed prevalent
overtreatment of low-risk disease but also identiﬁed what
appeared to be a troubling undertreatment of high-risk
disease [3, 11]. Interestingly, treatment patterns were found
to vary across clinical sites, and much of the variation
could be attributed to practice site itself and not solely
patient or tumor factors. Clinical practice site alone
explained, for example, 13% variation seen in ADT, 30%
in RP, 36% in brachytherapy, 20% in EBRT, and 74% in
cryoablation [11].
Another unique feature of CaPSURE is the access to
resource use data that offer a means of studying health care
cost implications of different prostate cancer management
strategies. Penson et al. [12] examined adjusted ﬁrst-year
costs associated with various treatment options based on
Medicare payment schedules and found a trend toward
higher costs for higher-stage patients. The mean cost of
prostate cancer treatment in the ﬁrst year after diagnosis
was $6,375 and was not different between patients with RP
and EBRT, but was higher for those receiving NADT prior
to either treatment. Wilson et al. [13] analyzed all health
care utilization of various treatments over a period of
5 years and found that the average annual cost was $7,740.
This varied widely with AS costing the least at $5,843 and
androgen deprivation therapy the most expensive at
$12,590.
Oncologic outcomes
Recent evidence suggests that information beyond
Gleason score obtained at diagnostic biopsy contributes
signiﬁcantly to accurate risk assessment among patients
with newly diagnosed prostate cancer. The percent of
positive biopsy cores was initially validated as a prog-
nostic marker among patients who underwent RP in
CaPSURE and was signiﬁcant across all risk groups,
conﬁrming that biopsy data obtained in the community
setting using non-standardized techniques and assessed
by diverse pathologists offers consistent and useful
prognostic information [14].
Cancer of the Prostate Risk Assessment score (CAPRA)
was developed using data from the CaPSURE registry. The
CAPRA score simply and accurately predicts pathologic
status, disease recurrence, and mortality after surgery [15].
Points are assigned based on age, clinical stage, PSA,
Gleason grade, and percent of cores positive on biopsy.
Scores range from 0 to 10 with each 2-point increase
roughly doubling the risk of recurrence and progression.
A 9-point variation of the CAPRA scoring system can
alternatively be used if data regarding percent positive
biopsy cores are not available. The strength of the CAPRA
score is not only in its ease of use but in its ability to better
discriminate between categories of risk in all practice set-
tings when compared with other nomograms [16, 17]. The
CAPRA score has been extensively validated in other
disease registries and academic cohorts, both in the United
States and Europe [18].
Uncertainty regarding the optimal treatment for local-
ized prostate cancer has led to large variation in practice
patterns as reported previously in CaPSURE [11]. To date,
no adequate randomized trials have compared active
treatments for localized prostate cancer due to difﬁculties
with accrual, randomization, high cost, and need for long
follow-up. Disease registries can provide important
insights into outcomes and can provide an important source
for comparative effectiveness analysis between various
treatments. This is highlighted in a recent study by Coo-
perberg et al. [19] which compared risk-adjusted disease-
speciﬁc and all-cause mortality after treatment of localized
prostate cancer with RP, EBRT, and primary ADT. After
adjusting for age, disease risk, and comorbidity, mortality
at 10 years was less likely in men who underwent RP than
EBRT or primary ADT, especially in men with interme-
diate or high-risk disease.
Quality of life outcomes
The preservation of health-related quality of Life
(HRQOL) is a priority in any discussion of prostate cancer
treatment and outcomes due to the long natural history of
disease. Any negative impact on quality of life must be
minimized, as patients may experience it for an extended
period of time. CaPSURE had proved to be an invaluable
resource for the prospective, longitudinal assessment of
patient-reported outcomes and it has enabled investigators
to successfully address a number of questions in this area
of prostate cancer research.
CaPSURE HRQOL data are reported by both patients
and physicians and provide insight into the differences
between outcomes. An early study by Litwin et al. [20]
found that physician assessment of treatment impact on
HRQOL underestimated the impact experienced by
patients, especially within general health parameters. When
impairment was noted, urologists reported on urinary and
sexual functions more often than pain in men who under-
went treatment for localized prostate cancer. Many aspects
268 World J Urol (2011) 29:265–271
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123of patient-reported HRQOL (physical function and general
health) have also been signiﬁcantly associated with sur-
vival in a similar cohort of men, over the course of disease
from diagnosis to after treatment [21]. These studies
highlight the continued importance of multidimensional,
patient-reported HRQOL assessment in current prostate
cancer treatment.
Using longitudinal HRQOL data within CaPSURE,
comparisons can be made between outcomes among
treatment options. Men who underwent RP had lower
scores on both disease-speciﬁc and general HRQOL
instruments immediately postoperative, which improved
signiﬁcantly at 1 year after treatment, and continued to
improve in the domain of sexual function in the second
year. Men who were treated with EBRT, AS, or primary
ADT had scores that were relatively stable, except for
sexual function, which declined with time. Overall, patients
who underwent RP had the greatest decline initially, but
also the greatest degree of recovery. Most men experienced
the greatest recovery of both urinary and sexual functions
within 2 years of treatment, with little change in reported
HRQOL scores after 3 years [22]. Those who received
multimodal therapy appeared to have greater declines in
urinary and sexual functions than those who were treated
with monotherapy [23].
Although prostate cancer presentation and treatment
patterns vary based on ethnicity, little was known with
regards to any differences in HRQOL. Disease registries
like CaPSURE are ideal to study ethnic groups that are
underrepresented in most clinical studies. Using CaP-
SURE data, African American men were found to have
lower HRQOL scores across many domains of QOL at
baseline and after treatment, but had higher sexual func-
tion scores [24]. Over time, African American patients
never recovered as well as white patients in reported
HRQOL scores. Ethnicity was also found to play a role in
primary treatment choice in men with equivalent disease
characteristics [25].
Although this article focuses primarily on lessons
learned from CaPSURE, there are a number of other US
national registries and databases available for research.
Table 2 highlights the strengths of many of the resources
available to study the various aspects of prostate cancer.
For example, the Prostate Outcomes Cancer Study
(PCOS), which utilizes Surveillance Epidemiology and
End Results (SEER)-based data, was initiated by the
National Cancer Institute (NCI) and used by investigators
to report on HRQOL outcomes in American men diag-
nosed with prostate cancer [26]. Likewise, the Department
of Defense Center for Prostate Disease Research (CPDR)
has been used to report on prostate cancer-speciﬁc mor-
tality and not only collects data on men with prostate
cancer treated within the military medical system but
seeks to standardize clinical practice among military sites
[27].
Limitations to disease registries in general center on
methodology of data collection. The quality of data col-
lected and integrity in data collection and follow-up
determine the quality of the disease registry. In addition to
bias introduced by data collection, disease registries do not
capture a random sample of the population. These biases
can be minimized (as in CaPSURE) by including com-
munity centers to increase population sampling. Central-
izing data collection and analysis with strict monitoring by
a statistician ensure quality control. Although CaPSURE
does capture a diverse group of men, patients are enrolled
by their urologists, rather than medical or radiation on-
cologists, which may exclude a proportion of men with
prostate cancer.
CaPSURE is a research partnership with industry (ini-
tially funded by TAP pharmaceuticals) under IRB approval.
Dataintegrityhasbeenmaintainedfreeofconﬂictofinterest
by thoughtful and transparent methodology and reporting.
Data analyses and decision for publication of CaPSURE
results have always rested with academic investigators
without the inﬂuence of industry. Currently, CaPSURE is
supported by a combination of gifted funds from Abbott
Laboratoriesalongwithagrowingportfoliooffederalgrants
to ensure registry continuity and maintenance.
Conclusion
While RCTs remain the gold standard for advancing
knowledge in medicine, they can be difﬁcult to complete
and expensive; moreover, in a disease with a prolonged
natural history, treatment strategies may evolve quickly
that even a well-executed trial may not be relevant by the
time it is published. Disease registries, like CaPSURE,
have provided a means to better understand many aspects
of prostate cancer epidemiology, practice patterns, out-
comes, and costs of care. It remains a robust source of
information and provides a cost-effective way of driving
evidence-based decisions regarding treatment and health
policy. Specialized observational disease registries such as
CaPSURE provide insight and have broad implications for
disease management and policy.
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